Market Cap
$88.52B
P/E Ratio
—
52W High
$254.48
52W Low
$22.28
Quality Score
MRNA scores 44/100 (D) — leverage is the strongest factor, profitability the weakest.
44
/ 100
See the full 7-factor breakdown with PRO.
UpgradeAI Technical Interpretation
PRO turns MRNA's RSI, MACD, moving averages, and Bollinger Bands into a plain-English read on trend, momentum, and volatility - context, not predictions.
Upgrade to PROAI “Why Did It Move?”
Get a ranked, evidence-grounded read on what's likely driving MRNA's move today — news, earnings, analyst activity, sector context, and technicals combined.
Upgrade to PROAnalyst Ratings23 analysts
Consensus & price targets via Yahoo Finance & Financial Modeling Prep. Not investment advice.
AI Fair Value Estimate
Get an AI analyst's take on whether MRNA looks cheap or expensive — a fair-value range with plain-English reasoning, in one click.
Upgrade to PROAI Earnings Preview
Next report 2026-11-06 · in 6 days
Consensus estimates
EPS
-$1.35
Revenue
$891.31M
Recent EPS surprises
Unlock the AI preview for MRNA
Get an AI analyst's read on the setup, what to watch, and risks heading into the print.
Upgrade to PROUnlock the post-earnings recap for MRNA
Get an AI analyst's read on how the report went and how the stock reacted.
Upgrade to PROInsider Trading50 recent filings
Buys
0
Sells
0
Reported value
$41.25M
| Date | Insider | Type | Shares | Price | Value | Owned |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | HOGE, STEPHEN President | Other | 76,452 | $0.00 | $0.00 | - |
| Oct 15, 2026 | HOGE, STEPHEN President | Other | 39,145 | $220.72 | $8.64M | - |
| Oct 15, 2026 | HOGE, STEPHEN President | Other | 76,452 | $12.21 | $933,478.92 | - |
| Oct 14, 2026 | HOGE, STEPHEN President | Other | 76,453 | $0.00 | $0.00 | - |
| Oct 14, 2026 | HOGE, STEPHEN President | Other | 76,453 | $12.21 | $933,491.13 | - |
| Oct 14, 2026 | HOGE, STEPHEN President | Other | 38,774 | $213.47 | $8.28M | - |
| Oct 14, 2026 | HOGE, STEPHEN President | Other | 450 | $214.15 | $96,367.50 | - |
| Oct 5, 2026 | MOCK, JAMES M Chief Financial Officer | Other | 704 | $190.01 | $133,767.04 | - |
| Oct 5, 2026 | MOCK, JAMES M Chief Financial Officer | Other | 1,454 | $0.00 | $0.00 | - |
| Oct 5, 2026 | MOCK, JAMES M Chief Financial Officer | Other | 1,454 | - | - | - |
| Sep 15, 2026 | HOGE, STEPHEN President | Other | 40,281 | $146.07 | $5.88M | - |
| Sep 15, 2026 | HOGE, STEPHEN President | Other | 76,452 | $12.21 | $933,478.92 | - |
| Sep 15, 2026 | HOGE, STEPHEN President | Other | 76,452 | $0.00 | $0.00 | - |
| Sep 14, 2026 | HOGE, STEPHEN President | Other | 76,453 | $0.00 | $0.00 | - |
| Sep 14, 2026 | HOGE, STEPHEN President | Other | 76,453 | $12.21 | $933,491.13 | - |
| Sep 14, 2026 | HOGE, STEPHEN President | Other | 40,294 | $144.13 | $5.81M | - |
| Sep 10, 2026 | MOCK, JAMES M Chief Financial Officer | Other | 19,836 | $30.96 | $614,122.56 | - |
| Sep 10, 2026 | MOCK, JAMES M Chief Financial Officer | Other | 19,836 | $134.49 | $2.67M | - |
| Sep 10, 2026 | MOCK, JAMES M Chief Financial Officer | Other | 15,000 | $134.49 | $2.02M | - |
| Sep 10, 2026 | MOCK, JAMES M Chief Financial Officer | Other | 19,836 | $0.00 | $0.00 | - |
| Sep 4, 2026 | KLINGER, SHANNON THYME Chief Legal Officer | Other | 11,797 | $0.00 | $0.00 | - |
| Sep 4, 2026 | KLINGER, SHANNON THYME Chief Legal Officer | Other | 5,704 | $148.87 | $849,154.48 | - |
| Sep 4, 2026 | KLINGER, SHANNON THYME Chief Legal Officer | Other | 11,797 | - | - | - |
| Sep 4, 2026 | MOCK, JAMES M Chief Financial Officer | Other | 11,797 | $0.00 | $0.00 | - |
| Sep 4, 2026 | MOCK, JAMES M Chief Financial Officer | Other | 5,704 | $148.87 | $849,154.48 | - |
| Sep 4, 2026 | MOCK, JAMES M Chief Financial Officer | Other | 11,797 | - | - | - |
| Sep 1, 2026 | MOCK, JAMES M Chief Financial Officer | Other | 2,475 | - | - | - |
| Sep 1, 2026 | MOCK, JAMES M Chief Financial Officer | Other | 1,197 | $140.34 | $167,986.98 | - |
| Sep 1, 2026 | MOCK, JAMES M Chief Financial Officer | Other | 2,475 | $0.00 | $0.00 | - |
| Sep 1, 2026 | KLINGER, SHANNON THYME Chief Legal Officer | Other | 3,471 | $30.96 | $107,462.16 | - |
| Sep 1, 2026 | HOGE, STEPHEN President | Other | 4,489 | $140.34 | $629,986.26 | - |
| Sep 1, 2026 | HOGE, STEPHEN President | Other | 9,283 | $0.00 | $0.00 | - |
| Sep 1, 2026 | HOGE, STEPHEN President | Other | 9,283 | - | - | - |
| Sep 1, 2026 | KLINGER, SHANNON THYME Chief Legal Officer | Other | 3,471 | $139.95 | $485,766.45 | - |
| Sep 1, 2026 | KLINGER, SHANNON THYME Chief Legal Officer | Other | 2,166 | - | - | - |
| Sep 1, 2026 | KLINGER, SHANNON THYME Chief Legal Officer | Other | 1,048 | $140.34 | $147,076.32 | - |
| Sep 1, 2026 | KLINGER, SHANNON THYME Chief Legal Officer | Other | 3,471 | $0.00 | $0.00 | - |
| Sep 1, 2026 | KLINGER, SHANNON THYME Chief Legal Officer | Other | 2,166 | $0.00 | $0.00 | - |
| Aug 28, 2026 | HOGE, STEPHEN President | Other | 611 | $0.00 | $0.00 | - |
| Aug 28, 2026 | MOCK, JAMES M Chief Financial Officer | Other | 329 | $0.00 | $0.00 | - |
| Aug 28, 2026 | MOCK, JAMES M Chief Financial Officer | Other | 160 | $142.77 | $22,843.20 | - |
| Aug 28, 2026 | MOCK, JAMES M Chief Financial Officer | Other | 329 | - | - | - |
| Aug 28, 2026 | KLINGER, SHANNON THYME Chief Legal Officer | Other | 329 | $0.00 | $0.00 | - |
| Aug 28, 2026 | KLINGER, SHANNON THYME Chief Legal Officer | Other | 160 | $142.77 | $22,843.20 | - |
| Aug 28, 2026 | KLINGER, SHANNON THYME Chief Legal Officer | Other | 329 | - | - | - |
| Aug 28, 2026 | HOGE, STEPHEN President | Other | 296 | $142.77 | $42,259.92 | - |
| Aug 28, 2026 | HOGE, STEPHEN President | Other | 611 | - | - | - |
| Aug 27, 2026 | KLINGER, SHANNON THYME Chief Legal Officer | Other | 375 | $149.66 | $56,122.50 | - |
| Aug 27, 2026 | KLINGER, SHANNON THYME Chief Legal Officer | Other | 774 | - | - | - |
| Aug 27, 2026 | HOGE, STEPHEN President | Other | 1,437 | $0.00 | $0.00 | - |
Insider transactions via Alpha Vantage with SEC EDGAR fallback. Data can include grants, planned sales, and administrative filings; this is not investment advice.
Financial Statements
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.94B | $3.20B | $6.85B | $18.88B | $17.74B |
| Gross Profit | $1.08B | $1.74B | $2.15B | $13.46B | $15.12B |
| Operating Income | -$3.07B | -$3.94B | -$4.24B | $9.42B | $13.30B |
| EBITDA | -$2.55B | -$3.39B | -$3.28B | $9.95B | $13.54B |
| Net Income | -$2.82B | -$3.56B | -$4.71B | $8.36B | $12.20B |
| EPS (Diluted) | $-7.26 | $-9.27 | $-12.34 | $20.10 | $28.29 |
Financial statements via Financial Modeling Prep. Figures as reported; not investment advice.
AI Stock Analysis
Unlock an in-depth, balanced bull/bear breakdown of MRNA — catalysts, risks, and a plain-language read on the fundamentals.
Upgrade to PROInvestor Copilot Notebook
Keep a thesis on MRNA
Save your buy/watch/avoid rationale, track it over time, and get an AI read on whether the data still backs it up.
Upgrade to PROInvestment Thesis Timeline
See MRNA's full timeline
Earnings surprises, news catalysts, insider activity, and your own notebook events — one dated, classified feed.
Upgrade to PRODeeper technical charting, indicators, and pattern tools that complement XMarketPro's research.
Open advanced chartsSponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.
Automated technical analysis, charting, and pattern recognition for active traders.
Explore automated technical analysisSponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.
Another independent research perspective to compare against XMarketPro's own analysis.
Compare with additional researchSponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.
A well-established U.S. brokerage for investors moving from research into execution.
Explore brokerage optionsSponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.
About Moderna, Inc.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Visit modernatx.comKey Statistics
- Open
- $221.11
- Prev Close
- $222.76
- Day High
- $227.53
- Day Low
- $217.22
- Volume
- 8.99M
- Market Cap
- $88.52B
- P/E Ratio
- —
- EPS
- -$7.98
- Beta
- 1.09
- Dividend Yield
- —
- 52W High
- $254.48
- 52W Low
- $22.28
- Analyst Target
- —